Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure. TRV027 is the most advanced drug in Trevena's pipeline, and currently the subject of a Phase 2a dose finding study in stable chronic heart failure patients. The Phase 1 first-time-in-human clinical study of the drug was successfully completed in 2010.

“We are delighted to have successfully translated the safety, tolerability, pharmacokinetics, and pharmacodynamics of TRV027 from preclinical species into humans. These Phase 1 data support the decision to progress TRV027, our first biased ligand, into the current Phase 2 study in heart failure patients”

David Soergel, M.D., Head of Clinical Development at Trevena, will present the poster entitled "First human dosing experience with TRV027, a novel therapy for acute heart failure," on Tuesday, September 11^th. The Phase 1 study of TRV027 was a single-dose, dose escalation, crossover study in two cohorts of healthy subjects. The aims of the study were to assess the safety, tolerability and pharmacokinetics of TRV027 and to inform dose selection and dosing for Phase 2 studies.

"We are delighted to have successfully translated the safety, tolerability, pharmacokinetics, and pharmacodynamics of TRV027 from preclinical species into humans. These Phase 1 data support the decision to progress TRV027, our first biased ligand, into the current Phase 2 study in heart failure patients," commented Maxine Gowen, Ph.D., President and CEO of Trevena.

Source Trevena, Inc.